The treatment of psoriasis with IL-10: rationale and review of the first clinical trials

Bibliography

• CHRISTOPHERS E, STERRY W: Psoriasis. In: Dermatology in General Medicine. Fitzpatric TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, (Eds.), McGraw-Hill, New York, USA (1993):489–515.
   Google Scholar
• VALDIMARSSON H, BAKER BS, JOHNSDOTTIR I, FRY L: Psoriasis: a disease of abnormal keratinocyte prolif-eration induced by T lymphocytes. Immunol. Today (1986) 7:256–259.
   PubMedGoogle Scholar
• NICKOLOFF BJ: The cytokine network in psoriasis. Arch. Dermatol. (1991) 127:871–884.
   PubMed Web of Science ®Google Scholar
• •A valuable overview regarding the role of cytokines in psoriasis.
   Google Scholar
• UYEMURA K, YAMAMURA M, FIVENSON DF, MODLIN RL, NICKOLOFF BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper Type 1 cell-mediated response. J. Invest. Dermatol. (1993) 101:701–705.
   PubMed Web of Science ®Google Scholar
• SCHLAAK JF, BUSLAU M, JOCHUM W et al: T cells involved in psoriasis vulgaris belong to the Th 1 subset. J. Invest. Dermatol. (1994) 102:145–149.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, KRANE JF, CARTER DM, GOTTLIEB AB: Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Invest. Dermatol. (1990) 94:135S–140S.
   Google Scholar
• OHTA Y, KATAYAMA I, FUNATO T et al.: In situ expres-sion of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch. Derm. Res. (1991) 283:351–356.
   PubMed Web of Science ®Google Scholar
• LEMSTER BH, CARROLL PB, RILO HR, JOHNSON N,NIKAEIN A, THOMSON AW: IL-8111-8 receptor expres-sion in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin. Exp. Immunol. (1995) 99:148–154.
   PubMed Web of Science ®Google Scholar
• ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol (1994) 96:146–151.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, FIVENSON DP, KUNKEL SL, STRIETER RM, TURKA LA: Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin. Immunol. Immunopathol (1994) 73:63–68.
   PubMedGoogle Scholar
• TAKASHIMA A, MORITA A: Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporine A treatment. J. Invest. Dermatol. (1991) 96:376–382.
   PubMed Web of Science ®Google Scholar
• JEGASOTHY By, ACKERMAN CD, TODO S, FUNG JJ, ABU-ELMAGD K, STARZL TE: Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol. (1992) 128:781–785.
   PubMed Web of Science ®Google Scholar
• ALTMEYER PJ, MATTHES U, PAWLAK F et al.: Antipsori-atic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. (1994) 30:977–981.
   Google Scholar
• ASADULLAH K, SCHMID H, FRIEDRICH M et al.: Influence of Monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis? Arch. Derm. Res. (1997) 289:623–630.
   PubMed Web of Science ®Google Scholar
• CHERNOFF AE, GRANOWITZ EV, SHAPIRO L et al.: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. (1995) 154:5492–5499.
   Google Scholar
• ••First report on IL-10 application in humans.
   Google Scholar
• VAN DEVENTER S, ELSON CO, FEDORAK RN: for the Crohn's disease study group. Multiple dose of intrave-nous interleukin-10 in steroid refractory Crohn's disease. Gastroenterology (1997) 113:383–389.
   Google Scholar
• WISSING KM, MORELON E, LEGENDRE C et al.: A pilottrial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation (1997) 64:999–1006.
   PubMed Web of Science ®Google Scholar
• FIORENTINO DF, BOND MW, MOSMANN TR: Two types of mouse T-helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J. Exp. Med. (1989) 170:2081–2095.
   Google Scholar
• ••Discovery of IL-10.
   Google Scholar
• ASADULLAH K, DOCKE WD, SABAT R, EBELING M, VOLK HD, STERRY W: Interleukin-10 in der dermatologie. Hautarzt. (1999) 50:12–19.
   PubMedGoogle Scholar
• D'ANDREA A, ASTE-AMEZAGA M, VALIANTE NM, MA X, KUBIN M, TRINCHIERI G: Interleukin 10 (IL10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. (1993) 178:1041–1048.
   PubMed Web of Science ®Google Scholar
• DE WAAL MALEFYT R, ABRAMS J, BENNETT B, FIGDORCG, DE VRIES JE: Interleukin 10 (IL10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of 11-10 produced by monocytes. J. Exp. Med. (1991) 174:1209–1220.
   PubMed Web of Science ®Google Scholar
• SPITS H, DE WAAL MALEFYT R: Functional characterization of human H.-10. Int. Arch. Immunol (1992) 99:8–15.
   Google Scholar
• •A valuable overview regarding the immunobiology properties of IL-10.
   Google Scholar
• PLATZER C, VOLK HD, PLATZER M: 5' noncoding sequence of human H.-10 gene obtained by oligo-cassette PCR walking. DNA Seq. (1994) 4:399–401.
   Google Scholar
• MEISEL C, VOGT K, PLATZER C, RANDOW F, LIEBENTHAL C, VOLK HD: Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur. j Immunol. (1996) 26:1580–1586.
   PubMed Web of Science ®Google Scholar
• MOORE KW, VIEIRA P, FIORENTINO DF, TROUNSTINE ML, KHAN TA, MOSMANN TR et al.: Homology of cytokine synthesis inhibitory factor (1-10) to the Epstein-Barr Virus gene BCRF1. Science (1990) 248:1230–1234.
   PubMed Web of Science ®Google Scholar
• RODE HJ, JANSSEN W, ROSEN-WOLFF A et al.: The genome of equine herpesvirus Type 2 harbors an 11-10 like gene. Virus Genes (1993) 7:111–116.
   PubMed Web of Science ®Google Scholar
• FLEMING SB, MCCAUGHAN CA, ANDREWS AE, NASH AD, MERCER AA: A homologue of H.-10 is encoded by the poxvirus orf virus. J. Vim]. (1997) 71:4857–4861.
   Google Scholar
• ZDANOV A, SCHALK-HIHI C, GUSTCHINA A, TSANG M, WEATHERBEE J, WLODAWER A: Crystal structure of H.-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure (1995) 3:591–601.
   Google Scholar
• WALTER MR, NAGABHUSHAN TL: Crystal structure of H.-10 reveals an interferon gamma-like fold. Biochem-istry (1995) 34:12118–12125.
   Google Scholar
• ZDANOV A, SCHALK-HIHI C, WLODAWER A: Crystal structure of human interleukin-10 at 1.6 A resolution and a model of a complex with its soluble receptor. Protein Sci. (1996) 5:1955–1962.
   Google Scholar
• ZDANOV A, SCHALK-HIHI C, MENON S, MOORE KW, WLODAWER A: Crystal structure of Epstein-Barr Virus protein BCRF1, a homologue of cellular IL-10. J. Mot. Biol. (1997) 268:460–467.
   PubMed Web of Science ®Google Scholar
• EALICK SE, COOK WJ, VIJAY-KUMAR S et al: Three-dimensional structure of recombinant human interferon-gamma. Science (1991) 252:698–702.
   PubMed Web of Science ®Google Scholar
• HO AS, LIU Y, KHAN TA, HSU DH, BAZAN JF, MOORE KW:A receptor for IL-10 is related to interferon receptors. Proc. Natl. Acad. Sci. USA (1993) 90:11627–11271.
   Google Scholar
• KOTENKO SV, KRAUSE CD, IZOTOVA LS, POLLACK BP,WU W, PESTKA S: Identification and functional charac-terization of a second chain of the 11-10 receptor complex. EMBO J (1997) 16:5894–5903.
   PubMed Web of Science ®Google Scholar
• SABAT R, SEIFERT M, VOLK HD, GLASER RW: Neutral-izing murine monoclonal anti-IL-10 antibodies enhances binding of antibodies against a different epitope. Mot. Immunol. (1996) 33:1103–1111.
   Web of Science ®Google Scholar
• REINEKE U, SCHNEIDER-MERGENER J; GLASER RW et al.:Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J. Mot. Recog. (1999) 12:1–7.
   Google Scholar
• REINEKE U, SABAT R; VOLK HD; SCHNEIDER-MERGENERJ: Mapping of the interleukin-10/interleukin-10 receptor combining site using structurally different peptide scans. Peptides (Proceedings of the Twenty-Fifth European Peptide Symposium) (1999) 510–511.
   Google Scholar
• REINEKE U, SABAT R, VOLK HD, SCHNEIDER-MERGENERJ: Mapping of the 11-10/I1-10 receptor combining site. Protein Sci. (1998) 7:951–954.
   PubMed Web of Science ®Google Scholar
• SPENCER SD, DI MARCO F, HOOLEY J et al.: The orphanreceptor CRFB4 is an essential subunit of the 11-10 receptor. J. Exp. Med. (1998) 187:571–578.
   PubMed Web of Science ®Google Scholar
• FINBLOOM DS, WINESTOCK KD: IL-10 induces the tyrosine phosphorylation of tyk2 and Jakl and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. (1995) 155:1079–1090.
   PubMed Web of Science ®Google Scholar
• FIORENTINO DF, ZLOTNIK A, MOSMANN TR, HOWARD M, 0"GARRA A: 11–10 inhibits cytokine production by activated macrophages. J. Immunol. (1 9 9 1) 147:3815-3822.
   Google Scholar
• MITRA RS, JUDGE TA, NESTLE FO, TURKA LA, NICKOLOFFBJ: Psoriatic skin-derived dendritic cell function is inhibited by exogenous 11–10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J. Immunol. (1995) 154:2668–2677.
   Google Scholar
• DE WAAL MALEFYT R, HAANEN J, SPITS H et al.:Interleukin 10 (11–10) and viral 11–10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. (1991) 174:915–924.
   Google Scholar
• ENK AH, ANGELONI VL, UDEY MC, KATZ SI: Inhibition of Langerhans cell antigen-presenting function by 11-10. Immunol. (1993) 151:2390–2398.
   Web of Science ®Google Scholar
• ROMAGNANI S: Biology of human Thl and Th2 cells. J. Chn. Immunol. (1995) 15:121–129.
   PubMed Web of Science ®Google Scholar
• KUHN R, LOHLER J, RENNICK D, RAJEWSKY K, MULLER W: Interleukin-10-deficient mice develop chronic entero-colitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• MUSSI A, BONIFATI C, CARDUCCI M et al.:11-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents. (1994) 8:117–120.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, STERRY W, STEPHANEK et al.: 11-10 is a key cytokine in psoriasis. J. Clin. Invest. (1998) 101:783–794.
   PubMed Web of Science ®Google Scholar
• •First report on IL-10 application in dermatology.
   Google Scholar
• ASADULLAH K, DOCKE WD, EBELING M et al.: 11-10 treatment of psoriasis - clinical results of A Phase II trial. Arch. Dermatol (1999) 135:187–192.
   PubMed Web of Science ®Google Scholar
• REICH K, BROCK M, GRAFE A, VENTE C, NEUMANN C, GARBE C: Treatment of psoriasis with Interleukin-10. J. Invest. Dermatol. (1998) 6:1235–1236.
   Google Scholar
• WEINSTEIN GD: Can immunomodulatory molecules work topically for psoriasis? J. Invest. Dermatol. (1996) 106:589.
   PubMed Web of Science ®Google Scholar
• NORRIS DA, TRAVES JB, LEUNG DYM: Lymphocyte activation in the pathogenesis of psoriasis. J. Invest. Dermatol. (1997) 109:1–4.
   PubMed Web of Science ®Google Scholar
• FERGUSON TA, DUBE P, GRIFFITH TS: Regulation of contact hypersensitivity by interleukin 10.1 Exp. Med. (1994) 179:1597–1604.
   PubMed Web of Science ®Google Scholar
• LI L, ELLIOT JF, MOSMANN TR: 11-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. (1994) 153:3967–3978.
   PubMed Web of Science ®Google Scholar
• ENK AH, SALOGA J, BECKER D, MOHAMADZADEH M, KNOP J: Induction of hapten-specific tolerance by interleukin 10 in vivo. J. Exp. Med. (1994) 179:1397–1402.
   PubMed Web of Science ®Google Scholar
• MICHEL G, GAILIS A, JARZEBSKA-DEUSSEN B, MUSCHEN A, MIRMOHAMMADSADEGH A, RUZICKA T: 1,25401-D2-vitamin D3 and calcipotriol induce 11-10 receptor gene expression in human epidermal cells. Inflamm. Res. (1997) 46:32–34.
   PubMed Web of Science ®Google Scholar
• BECHEREL PA, LEGOFF L, KTORZA S et al: Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratino-cytes. Eur. j Immunol. (1995) 25:2992–2995.
   PubMed Web of Science ®Google Scholar
• MICHEL G, MIRMOHAMMADSADEGH A, OLASZ E et al.: Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by 11-8, and up-regulation by an antipsoriatic glucocorti-costeroid in normal cultured keratinocytes. J. Immunol. (1997) 159:6291–6297.
   PubMed Web of Science ®Google Scholar
• REINEKE U, SABAT R, MISSELWITZ R et al: A synthetic mimic of a discontinuous binding site on interleukin-10. Nature Biotechnol (1999) 17:271–275.
   PubMed Web of Science ®Google Scholar